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Abstract
Background: Young age at portoenterostomy has been linked to improved outcome in biliary atresia, but pre-existing 
biological factors may influence the rate of disease progression. In this study, we aimed to determine whether 
molecular profiling of the liver identifies stages of disease at diagnosis.
Methods: We examined liver biopsies from 47 infants with biliary atresia enrolled in a prospective observational study. 
Biopsies were scored for inflammation and fibrosis, used for gene expression profiles, and tested for association with 
indicators of disease severity, response to surgery, and survival at 2 years.
Results: Fourteen of 47 livers displayed predominant histological features of inflammation (N = 9) or fibrosis (N = 5), 
with the remainder showing similar levels of both simultaneously. By differential profiling of gene expression, the 14 
livers had a unique molecular signature containing 150 gene probes. Applying prediction analysis models, the probes 
classified 29 of the remaining 33 livers into inflammation or fibrosis. Molecular classification into the two groups was 
validated by the findings of increased hepatic population of lymphocyte subsets or tissue accumulation of matrix 
substrates. The groups had no association with traditional markers of liver injury or function, response to surgery, or 
complications of cirrhosis. However, infants with an inflammation signature were younger, while those with a fibrosis 
signature had decreased transplant-free survival.
Conclusions: Molecular profiling at diagnosis of biliary atresia uncovers a signature of inflammation or fibrosis in most 
livers. This signature may relate to staging of disease at diagnosis and has implications to clinical outcomes.
Background
Biliary atresia results from a severe cholangiopathy that
obstructs extrahepatic bile ducts, disrupts bile flow, and
progresses to end-stage cirrhosis in most patients. With-
out knowledge of etiology and pathogenic mechanisms of
disease, all patients are subjected to the same surgical and
medical treatments despite the coexistence of different
clinical forms. Thus, new strategies to phenotype the
liver disease at diagnosis will aid the design of new clini-
cal protocols that take into account the patient's biologi-
cal makeup and facilitate studies of pathogenesis of
disease. Among several proposed pathogenic mecha-
nisms of disease [1,2], there is increasing evidence for an
inflammatory response in promoting bile duct injury. For
example, analysis of affected livers uncovered a promi-
nent expression of proinflammatory genes and evidence
of oligoclonal expansion of T lymphocytes at diagnosis
[3-5]. The biological relevance of these findings was sup-
ported by mechanistic experiments demonstrating the
roles of CD8+ lymphocytes or interferon-gamma in bile
duct injury in a mouse model of biliary atresia [6-8]. In
this mouse model, infection of newborn mice within the
first 2 days of birth results in an inflammatory obstruc-
tion of extrahepatic bile ducts within 1 week and atresia
by 12 to 14 days [9,10]. However, the extent to which indi-
vidual cell types and molecular circuits relate to disease
presentation and clinical course in humans is not well
established.
Potential factors affecting the clinical course of children
with biliary atresia include the center experience, age at
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portoenterostomy, and coexistence of embryonic malfor-
mations [11-17]. These factors notwithstanding, the pro-
gression of liver disease in most patients is the rule even
after the surgical removal of atretic bile ducts and resto-
ration of bile drainage, suggesting that biological factors
operative at the time of portoenterostomy might influ-
ence the outcome of liver disease. Using histological
approaches, previous studies linked the presence of
inflammation [18] and fibrosis [19-21] with poor clinical
outcome. Here, we aimed to determine whether molecu-
lar profiling of the liver identifies stages of disease at diag-
nosis. Analysis of liver biopsies uncovered a gene
expression signature of inflammation or fibrosis that was
associated with age at diagnosis and with differences in
transplant-free survival.
Methods
Study population, covariates and outcomes
T i s s u e  a n d  c l i n i c a l  d a t a  w e r e  o b t a i n e d  f r o m  s u b j e c t s
enrolled into a prospective study of patients with biliary
atresia evaluated at Cincinnati Children's Hospital Medi-
cal Center or into a multi-center prospective observa-
tional study carried out by the Biliary Atresia Research
Consortium, with informed consent obtained from all
infants' legal guardians. The study protocol conforms to
the ethical guidelines of the 1975 Declaration of Helsinki
and was approved by the human research committees of
all participating institutions. Subjects were enrolled if
diagnosed with biliary atresia and treated with portoen-
terostomy before 6 months of age. The diagnosis was
defined by an abnormal intraoperative cholangiogram
and histological demonstration of obstruction of extrahe-
patic bile ducts. Clinical and laboratory data were
obtained at surgery and at 3- to 6-month intervals for the
first 2 years of life (Additional file 1).
Liver phenotyping
Wedge liver biopsies were obtained at the time of por-
toenterostomy and snap-frozen in liquid nitrogen,
embedded frozen in OCT compound, or formalin fixed/
paraffin embedded. Levels of inflammation were quanti-
fied by grading the population of portal tracts by inflam-
matory cells using liver sections stained with
hematoxylin/eosin (graded 0 to 3 as described in Figure
1) and by counting cells immunostained with primary
antibodies against CD3 (CD3 complex, Dako, Carpinte-
r i a ,  C A ,  U S A ;  t o  i d e n t i f y  T  c e l l s ) ,  C D 1 1 b  a n d  C D 1 9
(EP1345Y and 2E2B6B10, respectively; both from Abcam,
Cambridge, MA, USA; to identify B and myeloid cells,
respectively), or CD56 (NCAM16.2, BD Biosciences, San
Jose, CA, USA; to identify natural killer (NK) cells), with
species-specific, fluorochrome-conjugated secondary
antibodies according to published protocols [3,7,8]. To
examine for fibrosis, sections were stained with
trichrome and scored 0 to 3 according to a staging system
published previously, with minor modifications (Figure 1)
[19], and by consensus of two pathologists.
Microarray and quantitative PCR
Genome-wide liver expression datasets were generated
for individual subjects using pools of biotinylated cRNAs
synthesized from 400 ng of total RNA isolated from 10 to
20 mg of frozen liver samples. cRNA pools were hybrid-
ized to oligonucleotide-based human HG-U133 Plus 2.0
Array (Affymetrix, Santa Clara, CA, USA) containing
54,681 probe sets, scanned, and monitored for specific
signals with GeneChip® Operating Software as described
previously [3,22,23]. Affymetrix CEL files were imported
into GeneSpring v7.3 (Agilent Technologies, Santa Clara,
CA, USA) and subjected to Robust Multichip Average
normalization. Detailed information on handling of liver
biopsy samples, protocols for RNA labeling, chip hybrid-
ization and signals, internal controls, normalization pro-
cedures, and analysis of gene expression were deposited
in Gene Expression Omnibus [GEO:GSE15235]. Quanti-
tative PCR was done in a real-time Mx3000P thermocy-
cler employing specific primers (Additional file 2) and
established protocols [3,22,23].
Molecular signatures
Using the GeneSpring platform, we performed standard
'per-gene' median normalization for the entire gene
expression dataset. Using 14 samples that were grouped
as either inflammation or fibrosis based on the differ-
ences in histological scores being ≥2, the levels of expres-
sion for individual probes were filtered based on fold
change >2 between the two groups. This yielded 304
probesets, which were then subjected to a Welch's t-test,
with a significance cutoff of 0.05 and Benjamini and
Hochberg false discovery rate (FDR) multiple testing cor-
rection (5% FDR), generating a list of 150 probesets.
To evaluate the predictive ability of the 150-probeset
signatures to identify inflammation or fibrosis, we
applied the supervised method of prediction analysis of
microarrays (PAM) [24-26]. In this approach, all genes
are reassessed according to their ability to separate indi-
vidual types; those genes that are less useful in discrimi-
nating between these types are eliminated. Classification
accuracy was assessed by a method of ten-times ten-fold
cross-validation using the R-Project and Bioconductor
package MCRestimate [24-26]. Briefly, the training set is
subdivided into ten equal parts. Nine parts are used for
training, then employed to make class predictions on the
tenth part, which is used as the test set. After each por-
tion has been used as the test set once, the division into
10 parts is done again and the 10-fold cross-validation is
repeated 10 times for a total of 100 runs (that is, class pre-
dictions are made on each sample exactly 10 times). WeMoyer et al. Genome Medicine 2010, 2:33
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applied this approach to the remaining 33 unclassified
samples and assigned them into groups of inflammation
or fibrosis. The accuracy of this classification method was
determined by finding a percent of samples correctly
classified in at least six out of ten predictions made on the
same sample as described previously [24-26].
Functional analysis of genes
The genes highly expressed in the groups of inflamma-
tion or fibrosis were analyzed separately for functional
themes using the Ingenuity Pathway Analysis 7.1 (Inge-
nuity Systems, Inc., Redwood City, CA, USA), using a
right-tailed Fisher's exact test (with Benjamini-Hoch-
berg/FDR correction) to evaluate for over-representation
and displaying as -log(P-value); -log values exceeding 1.30
were significant (P < 0.05). Gene groups were also evalu-
ated for biological relationship by searching for shared
transcription factor binding sites (TFBSs) within 1 kb
upstream of the transcription start sites of individual
genes using Genomatix Gems Launcher [27], with a level
of significance that includes FDR correction.
Statistical testing of molecular signatures with clinical data
Testing for association between molecular signatures or
histological groups with categorical variables (clinical
form, cholangitis, ascites, transplant/death by 2 years of
age) used Fisher's exact test. For quantitative dependent
variables (age at diagnosis, level of bilirubin or alanine
aminotransferase, weight Z score), means or medians
were tested using Kruskal-Wallis one-way ANOVA on
Ranks or two-sample Wilcoxon rank sum test (with con-
tinuity correction for age) when appropriate (two-sided
P-values). The relationship of molecular signature or his-
tological groups and age was assessed by the Gaussian
Kernel method, while the relationship to outcome was
examined by censored Kaplan-Meier. The R-package was
used for all statistical analysis [28].
Results
Histological scoring
A total of 47 subjects were included in the study based on
the availability of clinical data and tissue for analysis.
Liver biopsies for individual subjects were examined for
Figure 1 Representative photographs of portal tracts stained with hematoxylin/eosin (upper panel) used for grading of liver sections in 
biliary atresia based on the presence of inflammatory cells (scale bar on photo 3 = 50 μm). The lower panels depict liver sections stained with 
trichrome for staging based on the extent of fibrosis (scale bar on photo 3 = 250 μm).
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inflammation and the extent of fibrosis at diagnosis. For
inflammation, we focused on the population of inflam-
matory cells within the portal space because it contains
the primary site of biliary pathology and to avoid vari-
ables related to extra-medullary hematopoiesis that is
commonly present in the hepatic lobule. We found that
34 of 47 (72.3%) of the biopsies had scores ≥1 for both
inflammation and fibrosis (Additional file 3). Thus, we
calculated the differences in scores within individual
samples and identified biopsies displaying predominant
features of either inflammation or fibrosis based on a dif-
ferential score ≥2. Fourteen of 47 (30%) samples fell into
this category, of which 9 had prominent inflammation
and 5 had advanced fibrosis, while the remaining 70% had
mixed histological features (differential scores <2). Next,
we examined whether these 14 samples could be differen-
tiated at the molecular level, and whether the signatures
could identify other liver biopsies displaying molecular
profiles for inflammation or fibrosis even when they were
not evident by histology.
Grouping by molecular signature
Applying data filtering and two-way cluster analysis to
the genome-wide expression data for the 14 liver biop-
sies, we identified 150 probe-sets with >2-fold differential
expression (P < 0.05, 5% FDR; Figure 2a). This profile
contained 115 unique genes, of which 77 were over-
expressed in the inflammation group and 38 in the fibro-
sis group (Additional file 4). To examine whether the gene
expression signature could be applied to individual sam-
ples and group them into inflammation or fibrosis pro-
files, we first applied the PAM-based 10-fold cross-
validation method using the 150 probes against the entire
gene expression dataset for each one of the 14 biopsies
separately. Initial testing with PAM to identify a smaller
set of gene probes that could best characterize each group
showed that the removal of any gene probe increased
misclassification errors in cross-validation. Therefore,
using the entire set of 150 probes, PAM predicted the
inflammation group in 8 of the 9 livers with predominant
inflammation scores by histology; the remaining liver dis-
played a signature typical of the fibrosis group (infant 4 in
Figure 2a, b). PAM also predicted the fibrosis group in all
five biopsies previously classified as fibrosis based on pre-
dominant histological scores. We then used the same
approach to group the 33 infants with mixed histological
features (differential scores <2) into inflammation or
fibrosis based on their gene expression profiles. From this
cohort, 29 of 33 liver biopsies were classified as either
inflammation or fibrosis. Interestingly, this classification
was in agreement with 76% of the biopsies that had a dif-
ferential histological score = 1 for inflammation or fibro-
sis (Additional file 3). Collectively, the addition of 33
biopsies to the 14 other biopsies (with a revised classifica-
tion for biopsy 4 according to molecular profiling)
grouped 43 of 47 (91%) infants into either molecular
inflammation or fibrosis (Figure 2b). This pointed toward
the potential existence of prominent biological processes
at diagnosis that may be relevant to staging of disease.
Testing of biological plausibility
To determine whether individual molecular signatures
are supported by underlying biological processes and
linked to pathogenesis of disease, we sought validation of
the inflammation signature by quantifying the hepatic
population by lymphocyte subtypes and myeloid cells
(neutrophils and macrophages) using immunofluores-
c e n c e .  F o r  t h e s e  e x p e r i m e n t s ,  w e  o n l y  i n c l u d e d  l i v e r
biopsies that had a minimum of eight portal tracts per
individual histological section in order to maximize the
representation of the cell counts for each subject; the
classification into the groups of inflammation or fibrosis
was based on molecular profiles. Cell count showed an
increase in T and NK lymphocytes in portal tracts of sub-
jects in the inflammation group, which were approxi-
mately 2.4-fold more abundant than the fibrosis group (P
< 0.05; Figure 3).
For the fibrosis group, the trichrome staining previ-
ously used to stage fibrosis in individual liver sections
provided initial support for an accumulation of extracel-
lular matrix in diseased livers. Seeking further validation,
we determined the expression of several collagen genes
that were not part of the 150-probe gene list and found a
higher expression of several collagen-related genes in the
fibrosis group (Figure 4a, b). These complementary
approaches provided biological support for the use of
gene expression profiling to classify biopsies into inflam-
mation or fibrosis groups, and raised the possibility that
the 150-probe set contains genes related to pathogenesis
of disease.
Functional analysis of the genes overexpressed in the
inflammation group showed that three gene groups with
the highest levels of statistical significance related to
immune, hematological, and lymphatic systems, each
with 24 to 26 genes (P < 0.001; Figure 5). Analyzing the
TFBSs, genes that were up-regulated were functionally
related to 49 transcription factors based on shared bind-
ing sites (Additional file 5). Among these transcription
factors we highlight the sites for nuclear factor of acti-
vated T-cells (NFAT; 65 genes, P < 0.001) and nuclear fac-
tor (NF)kB (60 genes, P < 0.001; Figure 6a; Additional file
6) because both regulate immunity genes, but only the
pleiotropic transcription factor NFkB being previously
linked to biliary atresia [29,30]. Applying the same strate-
gies for the 38 genes overexpressed in the fibrosis group,
the functional groups with the highest levels of signifi-
cance contained much fewer genes (2 to 7 per group, P <
0.049; Figure 5) which, surprisingly, were not related toMoyer et al. Genome Medicine 2010, 2:33
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matrix production/clearance. As a group, the genes iden-
tified only six transcription factors, which included E2F
(38 genes, P < 0.001) and SP1 (38 genes, P = 0.001; Figure
6b; Additional file 6). E2F regulates cellular proliferation
and TGFβ1-induced expression of matrix substrates,
while SP1 is a potent inducer of extracellular matrix
expression by fibroblasts [31-33], but neither has been
linked to pathogenesis of biliary atresia.
Testing for clinical relevance
To explore whether the molecular groups of inflamma-
t i o n  o r  f i b r o s i s  h a v e  r e l e v a n c e  t o  c l i n i c a l  p r e s e n t a t i o n
and/or progression of disease, we performed association
tests between individual groups and clinical and labora-
tory parameters. We found no difference in sex, race, eth-
nic background, or clinical forms (perinatal or biliary
atresia-splenic malformation) between the groups (Table
1). At the time of diagnosis, patients in both groups had
similar degrees of hepatocellular injury or cholestasis
(based on serum levels of alanine aminotransferases and
bilirubin). There was no difference of serum bilirubin and
nutritional status at 3 and 6 months after surgery, or in
the percent of patients with episodes of cholangitis or
ascites (Table 1).
As a group, subjects in the inflammation group were
younger than those in the fibrosis group at the time of
diagnosis (median {25 to 75% ranges}: 55 {46.3 to 63} ver-
sus 71 {54 to 80}, P < 0.01). Although there was some
overlap in age at diagnosis, a probability density function
of age estimated by the Gaussian kernel method showed
that the centers of distribution were not equal (P < 0.01),
with several subjects with the fibrosis group diagnosed
beyond 80 days (Figure 7a). The association between
inflammation group and younger age at diagnosis raised
the possibility that the presence of inflammation reflects
an earlier stage of disease and may relate to clinical out-
come. To examine this possibility, we tested the associa-
tion between the two groups and clinical outcome at 2
years of age. We found that the fibrosis group was signifi-
cantly associated with death or need for liver transplanta-
tion (odds ratio 8.2, 95% confidence interval 0.84 to 424, P
= 0.04). Consistent with this finding, Kaplan-Meier sur-
Figure 2 Assignment of infants with biliary atresia into groups of inflammation or fibrosis at diagnosis. When the differences in histological 
scores were ≥2, 5 of 47 livers had advanced fibrosis and 9 had predominant portal inflammation (black lines). These 14 livers displayed 150 gene 
probes that were differentially expressed between the fibrosis and inflammation groups (P < 0.05; Welch's t-test and 5% FDR - depicted as cluster anal-
ysis in (a)). Applying this expression signature to the 33 subjects classified histologically as 'mixed' (or unclassified), PAM assigned 29 subjects into 
groups of fibrosis or inflammation (N = 20 and N = 9, respectively) (b). The cluster analyses depict gene expression as a color variation from red (high 
expression) to blue (low expression); yellow displays similar level between the groups. The numbers below the columns denote individual patients 
(listed in Additional file 3). *Patient 4 is included in both cluster analyses because PAM reclassified the liver into the fibrosis group.
* *
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vival analysis showed the fibrosis group was associated
with a significantly lower transplant-free survival when
compared to the inflammation group (P = 0.04; Figure
7b). Lastly, based on previous reports that age at portoen-
terostomy may influence long-term outcome, we per-
f o r m e d  b i n a r y  l o g i s t i c  r e g r e s s i o n  m o d e l i n g  a n d  f o u n d
that age alone at portoenterostomy did not influence out-
come (P = 0.46), but the probability of death or need for
Figure 3 Quantification of hepatic mononuclear cells in portal tracts. Immunofluorescence panels (left) identify the population of portal tracts 
by B lymphocytes (CD19), myeloid cells (neutrophils and macrophages: CD11b), NK cells (CD56), and T cells (CD3) in livers with a molecular signature 
of inflammation. Photos on the right depict the left photos after nuclear staining with DAPI (white bar = 50 μm). The graphs on the right show the 
average number (± standard deviation) of stained cells in portal tracts from six livers with the inflammation signature and from five with the fibrosis 
signature. *P < 0.05.
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Figure 4 Hepatic mRNA expression for collagen genes. (a) Hepatic mRNA expression for collagen genes in subjects comprising the inflammation 
(N = 17) or fibrosis (N = 26) groups by microarrays. (b) mRNA expression by real-time PCR is shown for a subset of collagen genes shown in (a). Results 
are shown as mean ± standard error for individual genes as a ratio to GAPDH; *P < 0.05 (P-values range from 0.048 to 3.6 × 10-7 in (a).
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transplant was influenced by molecular groups as a func-
tion of age at a P-value of 0.079 (Figure 7c).
It remained to be determined whether similar associa-
tions with age and transplant-free survival were present if
the variables were compared to subjects that were
grouped into inflammation or fibrosis using predominant
histological features alone. To address this possibility, we
grouped subjects according to the differences between
inflammation and fibrosis scores for each subject (Addi-
tional file 3). From the entire cohort of 47 subjects, 14
(30%) had a differential score of ≥1 for inflammation and
17 (36%) for fibrosis; the remaining 16 (34%) were unclas-
sified due to the differences between inflammation and
fibrosis being zero (Figure 8). Comparative analysis
between the inflammation and fibrosis groups showed no
differences in patient demographics, clinical forms (peri-
natal or biliary atresia-splenic malformation), mean
serum levels of conjugated bilirubin or alanine amin-
otransferases at diagnosis or at 3 months after hepatopor-
toenterostomy, weight Z-score, or incidence of
Figure 5 Functional grouping of genes that are up-regulated in 
inflammation (N = 77 genes) or fibrosis (N = 38 genes) groups us-
ing Ingenuity Pathways Analysis. Enrichment scores are represent-
ed as -log(P-value), with a threshold of 1.3 as the cut-off for significance 
(P < 0.05). Green arrows point to predominantly involved processes.
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cholangitis or ascites (Table 2). We also found no rela-
tionship of either group with age at diagnosis (P = 0.7;
Additional file 7a) or difference in survival with the native
liver at 2 years of age (P = 0.48, Additional file 7b). Thus,
grouping of subjects based on differences between histo-
logical scores did not show relationships with clinical
forms of disease, age at presentation, level of cholestasis
at diagnosis or after portoenterostomy, or need for trans-
plantation by 2 years of age.
Discussion
We found that most livers of infants with biliary atresia
display some elements of inflammation and fibrosis at
diagnosis, with a subset (30% of the biopsies) containing
more predominant histological features of either inflam-
mation or fibrosis based on a greater differential score for
the phenotypes. Using a gene expression signature highly
specific for this subset of livers, we were able to group
91% of the biopsies into molecular inflammation or fibro-
sis and found significant association with age at portoen-
terostomy and transplant-free survival. These findings
suggest that molecular profiling at diagnosis may stage
the liver disease by the identification of biological path-
ways that may not be easily distinguishable by standard
histological approaches to quantify inflammation or
fibrosis. This may be due to intrinsic limitations of mor-
phological methods (that is, hematoxylin/eosin or
trichrome staining) or to a sampling artifact caused by a
Table 1: Relationship between clinical and biochemical characteristics and molecular groups of inflammation and fibrosis 
in infants with biliary atresia
Patient characteristic Inflammation group, 
N = 15
Fibrosis group, N = 26 Total, N = 41a P-valueb
Sex, N (%)
Female 6 (40) 12 (46) 18 (44) 0.8
Male 9 (60) 14 (54) 23 (56)
Race, N (%)
White 11 (73) 19 (73) 30 (73) 1.0
Black 1 (7) 1 (4) 2 (5) 1.0
Asian 2 (13) 1 (4) 3 (7) 0.5
Other 1 (7) 5 (19) 6 (15) 0.6
Ethnicity, N (%)
Hispanic 1 (7) 1 (6) 5 (12) 0.6
Nonhispanic 14 (93) 25 (94) 36 (88)
Age in days, median 
(25-75%)
55 (46.3-63) 71 (54-80) 65 (50-75) <0.01
Clinical type
BASM N (%) 2 (13) 3 (12) 5 (12) 1.0
Perinatal N (%) 13 (87) 23 (88) 36 (88)
Mean CB at diagnosisc 4.9 ± 2.1 5.8 ± 2.4 5.5 ± 2.3 0.3
Mean ALT at diagnosisc 125 ± 83 154 ± 74 144 ± 78 0.3
Mean CB at 3 months 
after HPEc
1.7 ± 2.6 3.5 ± 5.3 2.8 ± 4.5 0.3
Weight Z-score at 6 
months after HPEc
-1.3 ± 1.1 -1.7 ± 1.2 -1.5 ± 1.2 0.4
Presence of 
cholangitis, N (%)
8 (53) 18 (72) 26 (63) 0.5
Presence of ascites, N 
(%)
4 (27) 12 (48) 16 (40) 0.3
aSix patients from the cohort of 47 patients are not included because they were 'unclassified' by gene expression profiling (N = 4) or dropped 
off the study before 2 years of age (N = 2). bP-values denote levels of statistical differences between the inflammation and fibrosis groups. 
cMean ± standard deviation. ALT, alanine aminotransferases; BASM, biliary atresia splenic malformation (polysplenia or asplenia); CB, 
conjugated bilirubin; HPE, hepatoportoenterostomy.Moyer et al. Genome Medicine 2010, 2:33
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non-uniform tissue injury that varies between anatomical
lobes and, perhaps more importantly, among neighboring
lobules and portal tracts. Both obstacles may be over-
come by the molecular profiling described herein. First, it
uses RNA isolated from a fragment of tissue that,
although small, contains a much larger representation of
lobules/portal tracts than individual histological sections.
Second, it is based on a molecular signature that contains
the collective expression behavior of gene groups, with-
out a priori bias related to their biological affiliations.
In experiments to validate the grouping of liver biopsies
based on molecular signatures, we found that some gene
groups are functionally related to the population of portal
tracts by inflammatory cells and to molecular circuits
previously implicated in pathogenesis of disease. For
example, livers with a molecular signature of inflamma-
tion had an increase in the number of T and NK lympho-
cytes, overexpressed genes related to the immune system,
and contained a cluster of genes with NFκB transcription
sites. The activation of NFκB was also reported in this
mouse model [29,30], but the enrichment of bindings
sites for NFAT and other transcription factors in the list
of genes that are differentially expressed suggests that
molecular networks regulated by these factors may be
important for the pathogenesis of disease. Despite the
activation of these molecular pathways within the inflam-
mation signature, we recognize that there might be dis-
tinctions between wedge and core liver biopsies. We were
unable to make a direct comparison between these two
types of biopsies due to the unavailability of tissues. Fur-
ther, the isolation of RNA from a liver biopsy fragment
may limit the potential implication of the findings with
regards to disease pathogenesis because the biopsy
includes several cell types and different regions of the
liver lobule. This type of study will benefit from the use of
laser-capture microdissection, which enables the analysis
of specific cell types or anatomical regions (that is, portal
tract versus lobule).
Gene expression profiling increases the number of
available methods to quantify prominent biological pro-
cesses in biliary atresia. A previous study used histologi-
cal staining methods and reported that a high degree of
Figure 7 Relationship between molecular groups and clinical fea-
tures. (a) The probability density function of age at the time of surgery 
(Kasai procedure) in relation to molecular signatures of inflammation 
or fibrosis in biliary atresia. The age of individual patients is shown be-
low the graph as short vertical bars. (b) Kaplan-Meier analysis shows a 
decreased survival with the native liver in infants with the fibrosis sig-
nature (P = 0.04). (c) Logistic regression modeling depicts the effect of 
age on the association between molecular groups and the probability 
of transplant or death by 2 years of age (P = 0.079).
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syncytial giant cells, focal and bridging necrosis, and
inflammation were associated with poor clinical outcome
[18,19]. These findings differ from the improved outcome
of our subjects assigned to the inflammation group, but
we recognize that our findings will require validation in a
larger population. Other studies have investigated the
association of hepatic fibrosis and clinical course after
portoenterostomy, with poor outcome reported for chil-
dren with advanced fibrosis, either quantified by standard
methods or aided by computerized morphometry [18-
21]. This association was reproduced in our study in the
children assigned to the group of molecular fibrosis.
The temporal differences in age at diagnosis for the
molecular groups raise the possibility that the gene
expression signatures reflect two distinct but inter-
related stages of disease. The first stage, represented by
younger patients with an inflammatory signature (most
often but not exclusively at younger age), is placed biolog-
ically earlier in pathogenesis of disease, while the other
patients may have transitioned to a more advanced stage
of fibrosis. Such a continuum in the pathogenesis of dis-
ease has been demonstrated in the rotavirus-induced
mouse model of biliary atresia [7,8,34], which begins with
prominent inflammation of the liver and extrahepatic bile
ducts and progresses to less inflammation and persistent
duct obstruction; however, in humans, the stages appear
not to obey a strict temporal organization. The presence
of fibrosis in a subset of younger infants suggests that age
alone cannot stage the disease. In these patients, the liver
injury may have started at an earlier age, or it may have
Table 2: Relationship between clinical and biochemical characteristics and histological groups in infants with biliary 
atresia
Patient characteristic Inflammatory 
subtype, N = 14
Fibrosing subtype, 
N = 17
Total, N = 31a P-valueb
Sex, N (%)
Female 5 (36) 6 (35) 11 (35) 1.0
Male 9 (64) 11 (65) 20 (65)
Race, N (%)
White 11 (79) 16 (94) 27 (87) 1.0
Black 0 (0) 0 (0) 0 (0) 1.0
Asian 2 (14) 1 (6) 3 (10) 1.0
Other 1 (7) 0 (0) 1 (3) 1.0
Ethnicity, N (%)
Hispanic 1 (7) 2 (12) 3 (10) 1.0
Nonhispanic 13 (93) 15 (88) 28 (90)
Age in days, median 
(25-75%)
63 (55-65) 66 (51-77) 63 (51-73) 0.3
Clinical type
BASM N (%) 1 (7) 1 (6) 2 (7) 1.0
Perinatal N (%) 13 (93) 16 (94) 29 (93)
Mean CB at diagnosisc 5.1 ± 1.6 5.8 ± 2.5 5.6 ± 2.2 0.5
Mean ALT at diagnosisc 196 ± 150 192 ± 120 194 ± 136 1.0
Mean CB at 3 months 
after HPEc
2.3 ± 3.7 3.0 ± 3.5 2.6 ± 3.6 0.7
Weight Z-score at 6 
months after HPEc
-1.1 ± 0.9 -1.8 ± 1.9 -1.4 ± 1.4 0.3
Presence of 
cholangitis, N (%)
5 (56) 10 (59) 15 (58) 1.0
Presence of ascites, N 
(%)
4 (36) 9 (53) 13 (47) 0.7
aSixteen subjects from the cohort of 47 patients are not included because the differences in histological scores for inflammation and fibrosis 
were zero. bP-values denote levels of statistical differences between inflammation and fibrosis groups. cMean ± standard deviation. ALT, 
alanine aminotransferases; BASM, biliary atresia splenic malformation (polysplenia or asplenia); CB, conjugated bilirubin; HPE, 
hepatoportoenterostomy.Moyer et al. Genome Medicine 2010, 2:33
http://genomemedicine.com/content/2/5/33
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undergone rapid progression to fibrosis. The possibility
of a rapid progression to fibrosis is supported by a previ-
ous report showing greater fibrogenesis in the livers of
n e o n a t a l  r a t s  w h e n  c o m p a r e d  t o  a d u l t s  i n  a  m o d e l  o f
cholestasis induced by bile duct ligation [35].
Molecular profiling of liver biopsies at the time of diag-
nosis has been shown to differentiate the embryonic and
perinatal forms of biliary atresia and identified genes with
potential roles in pathogenesis of the embryonic form of
disease [23]. For example, among the genes with unique
expression patterns were five imprinted genes (Igf2, Peg3,
Peg10, Meg3, and IPW) in infants with the embryonic
form, suggesting that a failure to down-regulate embry-
onic gene programs may be involved in the non-hepatic
malformations that are typical of this group of patients
[23]. In a separate study, molecular profiling also revealed
the activation of an interferon-gamma-rich proinflamma-
tory circuit [3]. The biological relationship between this
circuit and biliary injury was demonstrated in mechanis-
tic studies showing that the in vivo depletion of inter-
feron-gamma in mice prevented the obstruction of
extrahepatic bile ducts [8]. Despite the informative data
produced by these two studies, we recognize that the
approach described here to stage the disease using
molecular profiles needs future studies to evaluate its rel-
evance in clinical practice and in potential therapies. This
can be pursued by prospective validation in a new group
of patients adequately powered for statistical analysis to
look at clinical correlates and at responses to clinical
intervention. For example, will the 150-probe set be
reproduced if the same statistical method is applied to
new livers with histological scores ≥2 for inflammation or
fibrosis? Will infants with an inflammation signature do
better if treated with anti-inflammatory drugs (for exam-
ple, corticosteroids)? Formal answers to these questions
will ultimately reveal the clinical impact of staging of liver
disease and open opportunities for new trials that take
into account the patient's biological makeup.
Conclusions
Gene expression profiling of the liver at the time of diag-
nosis of biliary atresia identifies prominent signatures of
inflammation or fibrosis in most patients. These signa-
tures cannot be foreseen by traditional histological meth-
ods or by serum markers of liver injury or function. The
segregation of inflammation with younger age at diagno-
sis and of fibrosis with decreased survival is in keeping
with the ability of molecular profiling to stage the liver
disease at diagnosis.
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